US Patent Issued to KRIPTIC PHARMACEUTICALS on Sept. 8 for "Combination of markers for predicting the response to Vx-001" (French Inventors)

ALEXANDRIA, Va., Sept. 8 -- United States Patent no. 12,728,158, issued on Sept. 8, was assigned to KRIPTIC PHARMACEUTICALS Ltd. (Dublin).

"Combination of markers for predicting the response to Vx-001" was invented by Kostantinos (Kostas) Kosmatopoulos (Paris) and Jeanne Menez-Jamet (Montrouge, France).

According to the abstract* released by the U.S. Patent & Trademark Office: "The invention relates to the use of an anti-tumour vaccine composed of two peptides of nine amino acids-native cryptic TERT572 (RLFFYRKSV, SEQ ID No. 1), expressed by tumour cells, and the optimised variant thereof TERT572Y (YLFFYRKSV, SEQ ID No. 2), for the treatment of a tumour expressing telomerase reverse transcriptase (TERT), in an HLA-A*0201 patient with a no...